Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that exerts a huge burden on our society. The occurrence of this neurodegenerative disease has been increasing day-by-day. PD can be a serious concern if the patients are left untreated. However, conventional treatment has many side-effects and less bioavailability in the brain. Therefore, the necessary measurement is required to solve the limitations of PD treatment. Nanotechnology has made a major contribution to comprehend PD pathogenesis. Nanotechnology can provide efficient therapies that have reduced side-effects and increased bioavailability in the brain. This review emphasizes the emerging promise of nanoparticle-based treatment, drug delivery, and other therapeutic approaches for PD. Besides, the advantages of different approaches on nanotechnology platforms are far better over conventional therapy in the treatment of PD.
Keywords: Parkinson's disease, progressive neurodegenerative disorder, nanotechnology, nanoparticles, α-synuclein, blood-brain barrier.
Graphical Abstract
Current Drug Metabolism
Title:Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Volume: 22 Issue: 7
Author(s): Md. Marufur Rahman Moni, Mst. Marium Begum, Md. Sahab Uddin*Ghulam Md Ashraf*
Affiliation:
- Department of Pharmacy, Southeast University, Dhaka,Bangladesh
- Pre-clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah,Saudi Arabia
Keywords: Parkinson's disease, progressive neurodegenerative disorder, nanotechnology, nanoparticles, α-synuclein, blood-brain barrier.
Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that exerts a huge burden on our society. The occurrence of this neurodegenerative disease has been increasing day-by-day. PD can be a serious concern if the patients are left untreated. However, conventional treatment has many side-effects and less bioavailability in the brain. Therefore, the necessary measurement is required to solve the limitations of PD treatment. Nanotechnology has made a major contribution to comprehend PD pathogenesis. Nanotechnology can provide efficient therapies that have reduced side-effects and increased bioavailability in the brain. This review emphasizes the emerging promise of nanoparticle-based treatment, drug delivery, and other therapeutic approaches for PD. Besides, the advantages of different approaches on nanotechnology platforms are far better over conventional therapy in the treatment of PD.
Export Options
About this article
Cite this article as:
Moni Marufur Rahman Md. , Begum Marium Mst. , Uddin Sahab Md. *, Ashraf Md Ghulam*, Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease, Current Drug Metabolism 2021; 22 (7) . https://dx.doi.org/10.2174/1389200222666210202110129
DOI https://dx.doi.org/10.2174/1389200222666210202110129 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy and Adverse Effects of Venlafaxine in Children and Adolescents with ADHD: A Systematic Review of Non-controlled and Controlled Trials
Reviews on Recent Clinical Trials Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Pharmacogenetic and Pharmacogenomic Research in Psychiatry: Current Advances and Clinical Applications
Current Pharmacogenomics Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Stem Cells for the Treatment of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Drug-Induced Impulse Control Disorders: A Review
Current Clinical Pharmacology Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Deprescribing for Psychiatry: The Right Prescription?
Current Psychiatry Reviews Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry The Effectiveness of Treatments for Cocaine Dependence in Schizophrenic Patients: A Systematic Review
Current Neuropharmacology A Brief Overview of Tyrosine Hydroxylase and α-Synuclein in the Parkinsonian Brain
CNS & Neurological Disorders - Drug Targets Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Current Topics in Medicinal Chemistry HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies
Current Medicinal Chemistry Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Molecular Genetic of Human Male Infertility: From Genes to New Therapeutic Perspectives
Current Pharmaceutical Design Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets Revisiting the Medical Management of Parkinson’s Disease: Levodopa versus Dopamine Agonist
Current Neuropharmacology